LTC2422766I2 - Glikopirolato ir magnio stearato sausų miltelių kompozicijos - Google Patents

Glikopirolato ir magnio stearato sausų miltelių kompozicijos

Info

Publication number: LTC2422766I2
Authority: LT; Lithuania
Prior art keywords: glycopyrrolate; magnesium stearate; dry powder; powder formulations; stearate dry
Prior art date: 2004-04-30

Application number

LTPA2015053C

Other languages

English (en)

Original Assignee

Vectura Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-30

Filing date

2015-12-18

Publication date

2020-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2422766(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-18 Application filed by Vectura Limited filed Critical Vectura Limited

2020-02-10 Publication of LTC2422766I2 publication Critical patent/LTC2422766I2/lt

Links

HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 title 2
VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 title 1
238000009472 formulation Methods 0.000 title 1
229940015042 glycopyrrolate Drugs 0.000 title 1
235000019359 magnesium stearate Nutrition 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000000843 powder Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTPA2015053C 2004-04-30 2015-12-18 Glikopirolato ir magnio stearato sausų miltelių kompozicijos LTC2422766I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0409703.6A GB0409703D0 (en)	2004-04-30	2004-04-30	Pharmaceutical compositions
EP05738040A EP1755555B1 (en)	2004-04-30	2005-04-29	Methods for preparing dry powder compositions of glycopyrrolate

Publications (1)

Publication Number	Publication Date
LTC2422766I2 true LTC2422766I2 (lt)	2020-02-10

Family

ID=32408337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTPA2015053C LTC2422766I2 (lt)	2004-04-30	2015-12-18	Glikopirolato ir magnio stearato sausų miltelių kompozicijos

Country Status (26)

Country	Link
US (1)	US20080063719A1 (lt)
EP (3)	EP1755555B1 (lt)
JP (2)	JP5000483B2 (lt)
KR (1)	KR101287919B1 (lt)
CN (3)	CN1964700A (lt)
AU (2)	AU2005237266B2 (lt)
BR (1)	BRPI0510500B8 (lt)
CA (1)	CA2563760C (lt)
CY (6)	CY1113069T1 (lt)
DK (2)	DK2422766T3 (lt)
ES (2)	ES2546982T3 (lt)
GB (1)	GB0409703D0 (lt)
HU (4)	HUE025463T2 (lt)
IL (2)	IL178651A (lt)
LT (1)	LTC2422766I2 (lt)
LU (2)	LU92176I2 (lt)
MX (2)	MXPA06012493A (lt)
NO (1)	NO20065502L (lt)
NZ (1)	NZ550479A (lt)
PL (2)	PL2422766T3 (lt)
PT (2)	PT2422766E (lt)
RU (1)	RU2396943C2 (lt)
SG (3)	SG152292A1 (lt)
SI (2)	SI2422766T1 (lt)
WO (1)	WO2005105043A2 (lt)
ZA (1)	ZA200609350B (lt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0409703D0 (en) *	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
GB0525254D0 (en) *	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
GB0613161D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
BRPI0820745A2 (pt) *	2007-12-13	2015-06-16	Novartis Ag	Compostos orgânicos
ES2396471T3 (es) *	2007-12-13	2013-02-21	Novartis Ag	Procedimiento para reducir la tendencia de una sal de glicopirronio a agregarse durante el almacenamiento
US20100055045A1 (en)	2008-02-26	2010-03-04	William Gerhart	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CA2716936C (en) *	2008-02-26	2018-06-05	Elevation Pharmaceuticals, Inc.	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
DK2400950T3 (da)	2009-02-26	2019-07-29	Glaxo Group Ltd	Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
JP2012524815A (ja) *	2009-04-24	2012-10-18	シェーリングコーポレイション	乾燥粉末吸引器において有用な凝集体配合物
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
GB0921481D0 (en)	2009-12-08	2010-01-20	Vectura Ltd	Process and product
WO2011121425A1 (en) *	2010-03-31	2011-10-06	Glenmark Pharmaceuticals Limited	Pharmaceutical powder composition for inhalation
CN104257610A (zh)	2010-04-01	2015-01-07	奇斯药制品公司	用于制备可吸入干粉所用的载体颗粒的方法
PT2560611T (pt) *	2010-04-21	2018-02-07	Chiesi Farm Spa	Processo para proporcionar partículas com cargas eletrostáticas reduzidas
ES2705494T3 (es)	2010-08-31	2019-03-25	Glaxosmithkline Ip Dev Ltd	Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
AU2011298315B2 (en)	2010-08-31	2014-08-28	Glaxo Group Limited	Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) *	2011-03-04	2020-07-05	Heptares Therapeutics Ltd	استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CN104470503A (zh)	2012-04-13	2015-03-25	葛兰素史克知识产权开发有限公司	聚集粒子
AU2013100007B4 (en) *	2013-01-04	2013-05-23	Novartis Ag	System for treating chronic obstructive pulmonary disease
JP6114841B2 (ja)	2013-02-28	2017-04-12	ダーミラ，インク．Ｄｅｒｍｉｒａ，Ｉｎｃ．	グリコピロレート塩
US8558008B2 (en)	2013-02-28	2013-10-15	Dermira, Inc.	Crystalline glycopyrrolate tosylate
US9006462B2 (en)	2013-02-28	2015-04-14	Dermira, Inc.	Glycopyrrolate salts
SG11201507286QA (en)	2013-03-15	2015-10-29	Pearl Therapeutics Inc	Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) *	2013-03-28	2013-05-15	Vectura Ltd	New use
US9393202B2 (en) *	2013-04-26	2016-07-19	Chiesi Farmaceutici S.P.A	Particle size reduction of an antimuscarinic compound
GB201402556D0 (en)	2014-02-13	2014-04-02	Crystec Ltd	Improvements relating to inhalable particles
DK3689332T3 (da) *	2014-09-09	2026-03-23	Vectura Ltd	Formulering, som omfatter glycopyrrolat, fremgangsmåde og apparat
BR112017007587A2 (pt) *	2014-10-16	2018-01-30	Teva Branded Pharmaceutical Products R&D Inc	processo para preparar uma formulação farmacêutica em pó seca e inalável
US9925168B2 (en) *	2016-01-22	2018-03-27	Chiesi Farmaceutici S.P.A.	Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
BR112018067784A2 (pt)	2016-03-08	2019-01-15	Mereo Biopharma 1 Ltd	regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias
KR102762199B1 (ko)	2016-03-08	2025-02-07	메레오 바이오파마 1 리미티드	만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
PL3490533T3 (pl)	2016-07-29	2020-11-02	Inke, S.A.	Sposób stabilizacji rozmiaru cząstek
GEP20217239B (en)	2016-09-19	2021-03-25	Mexichem Fluor Sa De Cv	Pharmaceutical composition
WO2018167180A1 (en) *	2017-03-15	2018-09-20	Vectura Limited	Method and formulation
WO2019060604A1 (en) *	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	INHALABLE MEDICINE
WO2019060595A1 (en)	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
JP7280627B2 (ja)	2017-12-11	2023-05-24	メレオバイオファーマ１リミテッド	慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用
AU2018381874B2 (en)	2017-12-11	2024-08-15	Mereo Biopharma 1 Limited	Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
KR102696616B1 (ko)	2018-12-21	2024-08-20	한미약품 주식회사	흡입 제형용 건조 분말 및 이의 제조방법
US20250058063A1 (en)	2021-12-21	2025-02-20	Chiesi Farmaceutici S.P.A.	Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118414147A (zh)	2021-12-21	2024-07-30	凯西制药公司	填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2956062A (en) *	1959-02-26	1960-10-11	Robins Co Inc A H	Esters of amino alcohols
US3709039A (en) *	1970-08-31	1973-01-09	Gen Time Corp	Comfort humidity indicator
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) *	1995-04-07	1997-03-18	Edward Mendell Co., Inc.	Controlled release insufflation carrier for medicaments
GB9808470D0 (en)	1998-04-22	1998-06-17	Smithkline Beecham Plc	Novel process and apparatus
PL200941B1 (pl) *	1998-11-13	2009-02-27	Jagotec Ag	Suchy proszkowy preparat inhalacyjny
GB9826286D0 (en)	1998-12-01	1999-01-20	Rhone Poulence Rorer Limited	Process
GB9826284D0 (en) *	1998-12-01	1999-01-20	Rhone Poulence Rorer Limited	Process
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
JP5698423B2 (ja)	2000-06-27	2015-04-08	ベクトゥラ・リミテッド	医薬組成物で使用するための粒子の製造法
ES2474199T3 (es) *	2000-11-30	2014-07-08	Vectura Limited	Composiciones farmacéuticas para inhalaci�n
WO2002043702A2 (en) *	2000-11-30	2002-06-06	Vectura Limited	Pharmaceutical compositions for inhalation
PT1372608E (pt) *	2001-03-30	2008-01-04	Jagotec Ag	Formulações de aerossol médicas
EP1501479A1 (en) *	2002-05-07	2005-02-02	Nektar Therapeutics	Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) *	2003-09-15	2005-03-16	Vectura Ltd	Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) *	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
US7915303B2 (en) *	2005-03-24	2011-03-29	Sosei R&D Ltd.	Glycopyrronium salts and their therapeutic use

2004
- 2004-04-30 GB GBGB0409703.6A patent/GB0409703D0/en not_active Ceased
2005
- 2005-04-29 CN CNA200580013592XA patent/CN1964700A/zh active Pending
- 2005-04-29 US US11/587,725 patent/US20080063719A1/en not_active Abandoned
- 2005-04-29 EP EP05738040A patent/EP1755555B1/en not_active Revoked
- 2005-04-29 SI SI200531999T patent/SI2422766T1/sl unknown
- 2005-04-29 SG SG200903001-6A patent/SG152292A1/en unknown
- 2005-04-29 PT PT111906376T patent/PT2422766E/pt unknown
- 2005-04-29 SG SG2012093886A patent/SG186673A1/en unknown
- 2005-04-29 NZ NZ550479A patent/NZ550479A/en not_active IP Right Cessation
- 2005-04-29 KR KR1020067024763A patent/KR101287919B1/ko not_active Expired - Lifetime
- 2005-04-29 SI SI200531570T patent/SI1755555T1/sl unknown
- 2005-04-29 RU RU2006142322/15A patent/RU2396943C2/ru active Protection Beyond IP Right Term
- 2005-04-29 CN CN2010105642463A patent/CN102008453A/zh active Pending
- 2005-04-29 EP EP11190638A patent/EP2422767A3/en not_active Withdrawn
- 2005-04-29 EP EP11190637.6A patent/EP2422766B1/en not_active Revoked
- 2005-04-29 CN CN201710357916.6A patent/CN107252423A/zh active Pending
- 2005-04-29 PL PL11190637T patent/PL2422766T3/pl unknown
- 2005-04-29 SG SG10201605001SA patent/SG10201605001SA/en unknown
- 2005-04-29 ES ES11190637.6T patent/ES2546982T3/es not_active Expired - Lifetime
- 2005-04-29 BR BRPI0510500A patent/BRPI0510500B8/pt not_active IP Right Cessation
- 2005-04-29 AU AU2005237266A patent/AU2005237266B2/en active Active
- 2005-04-29 PL PL05738040T patent/PL1755555T3/pl unknown
- 2005-04-29 CA CA2563760A patent/CA2563760C/en not_active Expired - Lifetime
- 2005-04-29 WO PCT/EP2005/051980 patent/WO2005105043A2/en not_active Ceased
- 2005-04-29 MX MXPA06012493A patent/MXPA06012493A/es active IP Right Grant
- 2005-04-29 JP JP2007510045A patent/JP5000483B2/ja not_active Expired - Lifetime
- 2005-04-29 HU HUE11190637A patent/HUE025463T2/en unknown
- 2005-04-29 PT PT05738040T patent/PT1755555E/pt unknown
- 2005-04-29 ES ES05738040T patent/ES2388289T3/es not_active Expired - Lifetime
- 2005-04-29 DK DK11190637.6T patent/DK2422766T3/da active
- 2005-04-29 DK DK05738040.4T patent/DK1755555T3/da active
2006
- 2006-10-16 IL IL178651A patent/IL178651A/en active IP Right Review Request
- 2006-10-27 MX MX2012008068A patent/MX341426B/es unknown
- 2006-11-10 ZA ZA2006/09350A patent/ZA200609350B/en unknown
- 2006-11-29 NO NO20065502A patent/NO20065502L/no not_active Application Discontinuation
2011
- 2011-02-09 AU AU2011200543A patent/AU2011200543B2/en not_active Expired
- 2011-11-08 JP JP2011244443A patent/JP5124718B2/ja not_active Expired - Lifetime
2012
- 2012-08-13 CY CY20121100722T patent/CY1113069T1/el unknown
- 2012-12-10 IL IL223545A patent/IL223545A/en active IP Right Grant
2013
- 2013-03-13 HU HUS1300006C patent/HUS1300006I1/hu unknown
- 2013-03-27 LU LU92176C patent/LU92176I2/fr unknown
- 2013-03-29 CY CY2013012C patent/CY2013012I1/el unknown
2014
- 2014-03-07 LU LU92392C patent/LU92392I2/xx unknown
- 2014-03-19 CY CY2014015C patent/CY2014015I1/el unknown
2015
- 2015-08-27 CY CY20151100754T patent/CY1116655T1/el unknown
- 2015-12-18 LT LTPA2015053C patent/LTC2422766I2/lt unknown
- 2015-12-21 HU HUS1500072C patent/HUS1500072I1/hu unknown
- 2015-12-21 HU HUS1500073C patent/HUS1500073I1/hu unknown
- 2015-12-23 CY CY2015059C patent/CY2015059I1/el unknown
- 2015-12-23 CY CY2015060C patent/CY2015060I1/el unknown

Also Published As

Publication number	Publication date
SG152292A1 (en)	2009-05-29
HK1095282A1 (en)	2007-05-04
EP1755555B1 (en)	2012-05-23
BRPI0510500B1 (pt)	2019-04-24
CY2015060I1 (el)	2020-05-29
NO20065502L (no)	2007-01-24
HUE025463T2 (en)	2016-02-29
WO2005105043A2 (en)	2005-11-10
EP2422767A3 (en)	2012-04-25
PL2422766T3 (pl)	2015-11-30
CY2014015I2 (el)	2015-12-09
EP1755555A2 (en)	2007-02-28
EP2422766A3 (en)	2012-04-25
EP2422767A2 (en)	2012-02-29
AU2011200543A1 (en)	2011-03-03
JP5000483B2 (ja)	2012-08-15
SI2422766T1 (sl)	2015-10-30
SG186673A1 (en)	2013-01-30
DK1755555T3 (da)	2012-08-20
CN1964700A (zh)	2007-05-16
PL1755555T3 (pl)	2012-11-30
CY1113069T1 (el)	2015-08-05
KR20070033978A (ko)	2007-03-27
LU92176I2 (fr)	2013-05-27
WO2005105043A3 (en)	2006-05-04
HUS1500073I1 (hu)	2016-02-29
GB0409703D0 (en)	2004-06-02
LU92176I9 (lt)	2019-01-04
ZA200609350B (en)	2008-04-30
AU2005237266A1 (en)	2005-11-10
HUS1500072I1 (hu)	2016-02-29
SI1755555T1 (sl)	2012-10-30
BRPI0510500B8 (pt)	2021-05-25
IL178651A (en)	2012-12-31
CY2015059I1 (el)	2020-05-29
CN102008453A (zh)	2011-04-13
CY2013012I2 (el)	2015-08-05
IL223545A (en)	2016-04-21
KR101287919B1 (ko)	2013-07-18
ES2546982T3 (es)	2015-09-30
HK1167334A1 (en)	2012-11-30
IL178651A0 (en)	2007-02-11
SG10201605001SA (en)	2016-08-30
CN107252423A (zh)	2017-10-17
CA2563760A1 (en)	2005-11-10
LU92392I2 (fr)	2015-11-02
HUS1300006I1 (hu)	2016-07-28
BRPI0510500A (pt)	2007-10-30
DK2422766T3 (da)	2015-08-31
JP5124718B2 (ja)	2013-01-23
AU2011200543A8 (en)	2011-03-31
JP2012031209A (ja)	2012-02-16
RU2006142322A (ru)	2008-06-20
MX341426B (es)	2016-08-18
CA2563760C (en)	2013-07-02
AU2011200543B2 (en)	2012-11-29
PT1755555E (pt)	2012-08-17
RU2396943C2 (ru)	2010-08-20
CY2013012I1 (el)	2015-08-05
ES2388289T3 (es)	2012-10-11
CY1116655T1 (el)	2017-03-15
NZ550479A (en)	2009-11-27
JP2007535522A (ja)	2007-12-06
EP2422766B1 (en)	2015-06-24
CY2014015I1 (el)	2015-12-09
MXPA06012493A (es)	2007-01-29
US20080063719A1 (en)	2008-03-13
IL223545A0 (en)	2013-02-03
AU2005237266B2 (en)	2010-11-11
EP2422766A2 (en)	2012-02-29
PT2422766E (pt)	2015-10-12

Publication	Publication Date	Title
LTC2422766I2 (lt)	2020-02-10	Glikopirolato ir magnio stearato sausų miltelių kompozicijos
LTPA2017002I1 (lt)	2017-03-10	Aerozoliniai fluorchinolinai ir jų naudojimas
EP1848659A4 (en)	2009-08-12	DESOXYGENANT COMPOSITIONS AND PACKAGES COMPRISING SAID COMPOSITIONS
IL191287A0 (en)	2008-12-29	Atorvastatin formulation
IL184822A0 (en)	2007-12-03	Extended release formulation of levetiracetam
IL183762A0 (en)	2008-04-13	Direct compression formulation and process
IL188602A0 (en)	2008-06-05	Non-flammable insecticide composition and uses thereof
IL185199A0 (en)	2008-01-06	Indole compound and use thereof
GB0512940D0 (en)	2005-08-03	Compounds and their use
SI2101574T1 (sl)	2016-11-30	Spojine in oblike, primerne za lovljenje radikalov
IL185223A0 (en)	2008-06-05	Compounds and uses thereof
EP1722639A4 (en)	2008-01-23	PROTECTED DRY COMPOSITES
GB0520743D0 (en)	2005-11-23	Compounds and their use
EP1967533A4 (en)	2011-01-12	PHOTORADICALALLY AND THERMALLY RADIALLICALLY CURABLE COMPOSITION
EP1911744A4 (en)	2010-06-02	TRYPTOPHANDERIVATE AND ITS USE
GB0515974D0 (en)	2005-09-07	Compounds and imaging methods
NO20055559L (no)	2007-05-25	Plugg og fremgangsmate ved bruk av samme
IL191786A0 (en)	2008-12-29	Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
AU306780S (en)	2006-05-15	Handle and flange
AU306389S (en)	2006-04-10	Handle and flange
AU306782S (en)	2006-05-15	Handle and flange
AU306911S (en)	2006-05-22	Handle and flange
AU307086S (en)	2006-05-29	Handle and flange
AU306778S (en)	2006-05-15	Handle and flange
AU306915S (en)	2006-05-22	Handle and flange